Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROUGH-2 phase 2 trial of MAR002 in acromegaly
MOH_2026-09-10_017028Phase 2Not yet recruiting
- Sponsor
- Marea Therapeutics
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MAR002 in acromegaly (4 arms), sponsored by Marea Therapeutics. Primary endpoints: Safety and tolerability and Percent change in serum IGF-1 from baseline. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
MAR002
03
Conditions
acromegaly
Beyond the preview
Go deeper on MOH_2026-09-10_017028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-10_017028.